-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai, October 11, 2021/PRNewswire/ - On September 30, 2021, Boehringer Ingelheim-Eli Lilly jointly announced that it has formally submitted its Diabetes Alliance's SGLT2 to the China National Medical Products Administration Center for Drug Evaluation Inhibitor Otangjing® (generic name: Enpagliflozin tablets) is used for the registration application of new indications for adult patients with heart failure with preserved ejection fraction
Heart failure is a set of complex clinical syndromes caused by abnormal changes in the structure and/or function of the heart caused by various reasons, which cause ventricular contraction and/or diastolic dysfunction.
The registration application of Otangjing® for the indications of heart failure in adult patients with preserved ejection fraction is based on the EMPEROR-Preserved Phase III clinical trial.
Dr.
Dr.
[i] GBD 2016 Disease and Injury Incidence and Prevalence Collaborators.
[ii] Gurwitz JH, Magid DJ, Smith DH, Goldberg RJ, McManus DD, Allen LA, Saczynski JS, Thorp ML, Hsu G, Sung SH, Go AS.
[iii] China-HF
[iv] Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H; CHART-2 Investigators.
[v] REPRESENT-HF study.
[vi] Shah SJ, Borlaug B, Kitzman D, et al.
[vii] Ponikowski P, Anker SD, AlHabib KF, et al.
Source: Boehringer Ingelheim